Cardiovascular Strategic Roundup: Device Innovation and Treatment Value | Oct 01 – Nov 04, 2026
Cardiovascular technology trends signal a competitive shift toward…
Evestia Clinical Acquires Emtex Life Science | Lucid Diligence Brief
This Lucid Diligence Brief examines Evestia Clinical’s acquisition of Emtex…
Endocrinology Strategic Roundup: Access and Innovation | Sep 29 – Nov 2, 2026
Endocrinology market trends signal growing competition around treatment access,…
BioMarin’s $475M Fabry Disease Licensing Deal | Lucid Diligence Brief
This Lucid Diligence Brief explores BioMarin’s expansion of its Fabry disease…
RFU and Xcellerant Ventures: Jetstream Partnership | Lucid Diligence Brief
This Lucid Diligence Brief explores Rosalind Franklin University and Xcellerant…
Samsung Bioepis and Teva Expand SB41 and SB44 Biosimilar Partnership | Lucid Diligence Brief
This Lucid Diligence Brief explores Samsung Bioepis’ expansion of its…
Cardiovascular Strategic Roundup: Beyond Device Innovation | Aug 27 – Sept 30, 2026
Cardiovascular intervention is entering a new competitive phase, as…
Endocrinology Strategic Roundup: Beyond Glycemic Control | Aug 25 – Sept 28, 2026
Endocrinology Current Trends: For pharma teams, the competitive question is…
Merck–SciBrunch SPR2015: A $400M Preclinical Bet | Lucid Diligence Brief
This Lucid Diligence Brief examines Merck’s licensing deal for SciBrunch’s…
Basecamp Research $140M Series C: The Translation Test | Lucid Diligence Brief
This Lucid Diligence Brief examines Basecamp Research’s $140M Series C and…
QC Healthcare–Sanguina Collaboration: Can Digital Biomarkers Scale? | Lucid Diligence Brief
This Lucid Diligence Brief examines the QC Healthcare–Sanguina digital…
AbbVie–Iambic AI Drug Discovery Collaboration: Strategic Implications | Lucid Diligence Brief
This Lucid Diligence Brief examines the AbbVie–Iambic AI drug discovery…